## FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	s)														
Name and Address of Reporting Person *  Mann Brenda				2. Issuer Name and Ticker or Trading Symbol EYEGATE PHARMACEUTICALS INC [EYEG]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director X Officer (give title below)  VP of Research & Development					
(Last) (First) (Middle) C/O EYEGATE PHARMACEUTICALS, INC., 271 WAVERLEY OAKS ROAD, SUITE 108				3. Date of Earliest Transaction (Month/Day/Year) 08/03/2021								VP 01 Re	esearch & Do	evelopment		
(Street) WALTHAM, MA 02452				4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line)  _X_Form filed by One Reporting PersonForm filed by More than One Reporting Person						
(City) (State) (Zip)			Table I - Non-Derivative Securities Acqui						ired, Disposed of, or Beneficially Owned							
1.Title of Security (Instr. 3)		2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)		if Co (In	(Instr. 8)		(A) or Disposed of (D) (Instr. 3, 4 and 5)		of	5. Amount of Securities Beneficially Owned Followi Reported Transaction(s) (Instr. 3 and 4)		ollowing	Ownership of Form: EDirect (D) or Indirect (	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
						(	Code	V	Amoun	(A) or (D)	Price				(I) (Instr. 4)	
Common	Stock		08/03/2021			]	F <sup>(1)</sup>		63		\$ 2.4	15,321			D	
Reminder:	Report on a s	separate line fo	r each class of secur	Derivativ	e Secur	ities A	cquire	Pers cont the f	ons wh ained ir orm dis	o respore this for plays a of	m are curre eficial	e not requ ntly valid	OMB con	formation spond unle trol numbe	ess	1474 (9-02)
1. Title of	2	3. Transaction		e.g., puts, 4.	calls, v	varrar 5.	its, op		convert ate Exerc	ible secur		itle and	8 Price of	9. Number	of 10.	11. Natur
	Conversion or Exercise Price of Derivative Security	Date	Execution Da (Year) any	te, if Transaction Code (Instr. 8)		Num of Deri Secu Acqu (A) G Disp of (I (Inst	Number		and Expiration Date (Month/Day/Year)		Ame Und Seco	ount of lerlying urities tr. 3 and		Derivative Securities Beneficially Owned Following Reported Transaction ((Instr. 4)	Owners Form o Derivat Security Direct ( or Indir	hip of Indired Beneficia Ownersh (Instr. 4)  ect
				Cod	ode V	(A)	(D)	Date Exer		Expiration Date	Title	Amount or Number of Shares				

### **Reporting Owners**

	Relationships						
Reporting Owner Name / Address		10% Owner	Officer	Other			
Mann Brenda C/O EYEGATE PHARMACEUTICALS, INC. 271 WAVERLEY OAKS ROAD, SUITE 108 WALTHAM, MA 02452			VP of Research & Development				

### **Signatures**

/s/ Sarah Romano, Attorney-in-Fact*	08/04/2021		
**Signature of Reporting Person	Date		

### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Sale of shares to cover taxes due on restricted stock that vested on 08/01/2021.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.